Median Survival for Diseases by Risk Prognosis Status in Bleeding Versus Nonbleeding Patients
| . | Good-Risk Prognosis . | Poor-Risk Prognosis . | ||
|---|---|---|---|---|
| NBLD . | BLD . | NBLD . | BLD . | |
| ALL | 17.9 | 10.9 (P = .33) | 30.5 | 3.5 (P < .0001) |
| AML | 20.6 | 11.8 (P = .055) | 13.9 | 7.8 (P = .091) |
| CML | >39 | 3.8 (P < .0001) | 7.2 | 1.8 (P = .0002) |
| HD | >87.8 | 4.0 (P < .0001) | 22.0 | 3.6 (P = .006) |
| NHL | >58.8 | 19.6 (P = .0013) | 4.1 | 2.5 (P = .0063) |
| . | Good-Risk Prognosis . | Poor-Risk Prognosis . | ||
|---|---|---|---|---|
| NBLD . | BLD . | NBLD . | BLD . | |
| ALL | 17.9 | 10.9 (P = .33) | 30.5 | 3.5 (P < .0001) |
| AML | 20.6 | 11.8 (P = .055) | 13.9 | 7.8 (P = .091) |
| CML | >39 | 3.8 (P < .0001) | 7.2 | 1.8 (P = .0002) |
| HD | >87.8 | 4.0 (P < .0001) | 22.0 | 3.6 (P = .006) |
| NHL | >58.8 | 19.6 (P = .0013) | 4.1 | 2.5 (P = .0063) |
The adverse effect of bleeding was shown in both good- and poor-risk prognosis within each diagnosis. The median is given in months. P values compare BLD and NBLD groups in each risk group.